The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: Subadditivity, additivity or synergism?

Elie Rassy, Ziad Bakouny, Tarek Assi, Fadi El Karak, Nicholas Pavlidis

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    12 Citations (Scopus)

    Résumé

    The hypothesis that the interaction of chemotherapy and immune checkpoint inhibitors (ICIs) is synergistic has not been formally validated. The frontline ICI Phase II/III trials in advanced non-small-cell lung cancer were reviewed for the objective response rates (ORRs) and grade 3-5 adverse events (AEs) of ICI-chemotherapy combinations and those of each individual drug. The expected ORR and grade 3-5 AE of ICI-chemotherapy combinations were computed as the arithmetic sum of the pooled effects of each drug. Statistical pooling was performed using a double arcsine transformation and a random-effects model. Our findings suggest an enhanced effect that is less than additive for the ICI-chemotherapy combinations since the actual ORR and grade 3-5 AE were found to be less than the expected additive effect.

    langue originaleAnglais
    Pages (de - à)913-920
    Nombre de pages8
    journalImmunotherapy
    Volume11
    Numéro de publication10
    Les DOIs
    étatPublié - 1 janv. 2019

    Contient cette citation